Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALFA-9803: Intensive vs Less Intensive Post-Remission Therapy in Elderly AML
NCT00363025Phase 3Terminated
- Sponsor
- Acute Leukemia French Association
- Start
- Nov 1999
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of idarubicin, daunorubicin in acute myeloid leukemia (AML), myelodysplastic syndrome, refractory anemia with excess blasts (RAEB), sponsored by Acute Leukemia French Association. Started Nov 1999; status: terminated.
02
Drugs
idarubicindaunorubicin
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome, refractory anemia with excess blasts (RAEB)
Beyond the preview
Go deeper on NCT00363025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00363025.